Bisphosphonate drug holidays--when, why and for how long?

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Bisphosphonates are primary osteoporosis treatments, reducing fracture risks.
• Long-term bisphosphonate use is linked to osteonecrosis of the jaw and atypical fractures.
• Oversuppression of bone turnover may cause these adverse effects.

Purpose of the Study:

• To explore the concept and implications of bisphosphonate drug holidays.
• To review current evidence on the benefits and risks of bisphosphonate therapy cessation.
• To guide decisions regarding the continuation or recommencement of osteoporosis treatment.

Main Methods:

• Review of existing literature on bisphosphonate therapy and drug holidays.
• Analysis of data from studies on postmenopausal women regarding treatment continuation.
• Evaluation of factors influencing fracture risk and adverse event development.

Main Results:

• Bisphosphonate continuation benefits high-risk patients (T-score < -2.5 or prevalent vertebral fractures).
• Suggested drug holiday durations: up to 5 years for alendronate, 3 for zoledronate, 1 for risedronate.
• No definitive evidence proves drug holidays reduce adverse event risks.

Conclusions:

• Bisphosphonate drug holidays are a strategy to mitigate long-term risks.
• Treatment continuation may be beneficial for high-risk individuals.
• Reassessment of bone mineral density and fracture risk should guide treatment decisions.